In 1996, Ciba-Geigy merged with Sandoz to form Novartis in a transaction valued at approximately $36.3 billion, among the largest pharmaceutical mergers of its era. The combination created what was then the world's second-largest drugmaker and was projected to deliver roughly $1.5 billion in annual cost savings. Swiss markets welcomed the announcement, with both companies' shares rising sharply.